SCHEMBL2953357

SCHEMBL2953357

CO/C=C(/C(=O)O)c1ccccc1Oc1cccc(OS(=O)(=O)c2ccccc2)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.45
KDM4E B2RXH2 2/20 0.41
POLB P06746 1/20 0.41
ALDH1A1 P00352 6/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
CTNNB1 P35222 1/20 0.37
LMNA P02545 4/20 0.36
HTT P42858 3/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
RAB9A P51151 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
EYA2 O00167 1/20 0.36
GAA P10253 1/20 0.36
F2 P00734 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2953361 1.00 MAPT (0.45) MAPTKDM4EPOLBALDH1A1SMN1; SMN2
SCHEMBL29709963 0.91 MAPT (0.44) MAPTKDM4EPOLBALDH1A1SMN1; SMN2
SCHEMBL9152637 0.91 MAPT (0.44) MAPTKDM4EPOLBALDH1A1SMN1; SMN2
SCHEMBL204854 0.91 MAPT (0.44) MAPTKDM4EPOLBALDH1A1SMN1; SMN2
SCHEMBL2953359 0.90 MAPT (0.48) MAPTKDM4EPOLBALDH1A1SMN1; SMN2
SCHEMBL7131299 0.88 SMN1; SMN2 (0.42) MAPTKDM4EPOLBALDH1A1SMN1; SMN2
SCHEMBL2107595 0.85 KDM4E (0.57) KDM4EPOLBALDH1A1CTNNB1LMNA
SCHEMBL2107591 0.85 KDM4E (0.57) KDM4EPOLBALDH1A1CTNNB1LMNA
SCHEMBL2855935 0.85 KDM4E (0.57) KDM4EPOLBALDH1A1CTNNB1LMNA
SCHEMBL9420371 0.83 BRAF (0.50) ALDH1A1LMNAHTTPTGDR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240041028-A1 DELIVERY SYSTEM FOR PLANT PROTECTION OMYA INTERNATIONAL AG (CH) 2024-02-08 US disclosed
US-11882834-B2 Microbiocidal thiazole derivatives SYNGENTA PARTICIPATIONS AG (CH) 2024-01-30 US disclosed
EP-4271185-A1 DELIVERY SYSTEM FOR PLANT PROTECTION Omya International AG (CH) 2023-11-08 EP disclosed
EP-3244732-B1 USE OF SURFACE-REACTED CALCIUM CARBONATE AS CARRIER FOR AGROCHEMICAL COMPOUNDS OMYA INT AG (CH) 2023-05-03 EP disclosed
US-11629129-B2 Microbiocidal picolinamide derivatives SYNGENTA PARTICIPATIONS AG (CH) 2023-04-18 US disclosed
US-11629138-B2 Microbiocidal picolinamide derivatives SYNGENTA PARTICIPATIONS AG (CH) 2023-04-18 US disclosed
US-11566140-B2 Exterior coating composition TROY CORPORATION (US) 2023-01-31 US disclosed
US-20220279703-A1 APPARATUS AND METHOD FOR REDUCING DUST DEVELOPMENT IN PRECISION DRILL SOWING SYNGENTA PARTICIPATIONS AG (CH) 2022-09-08 US disclosed
WO-2022144403-A1 DELIVERY SYSTEM FOR PLANT PROTECTION OMYA INTERNATIONAL AG (CH) 2022-07-07 WO disclosed
US-20210186022-A1 MICROBIOCIDAL THIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2021-06-24 US disclosed
US-20150133506-A1 1-ARYL-5-ALKYL PYRAZOLE DERIVATIVE COMPOUNDS, PROCESSES OF MAKING AND METHODS OF USING THEREOF AVENTIS AGRICULTURE (FR) 2015-05-14 US disclosed
US-8822689-B2 Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof MERIAL LIMITED (US) 2014-09-02 US disclosed
US-20140080862-A1 ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF AVENTIS AGRICULTURE (FR) 2014-03-20 US disclosed
US-8314146-B2 Thioamide compounds, method of making and method of using thereof MERIAL LIMITED (US) 2012-11-20 US disclosed
US-7759381-B2 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof AVENTIS AGRICULTURE (FR) 2010-07-20 US disclosed
US-20080312272-A1 ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF MERIAL, INC. 2008-12-18 US disclosed
US-20080031902-A1 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof MERIAL, INC. 2008-02-07 US disclosed
US-6846777-B2 Synergistic biocidal composition THOR GMBH (DE) 2005-01-25 US disclosed
US-20030199490-A1 Synergistic biocidal composition THOR GMBH (DE) 2003-10-23 US disclosed
US-5466693-A FOE USE IN THE CULTIVATION OF RICE IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1995-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11882834-B2 Microbiocidal thiazole derivatives MSR1, TLR1, IFNG MAPT 4168/4885KDM4E 3260/4885POLB 3655/4885
US-20080031902-A1 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof CBR3, CBR1, NR5A2 MAPT 4885/4885KDM4E 3125/4885POLB 4202/4885
US-20080312272-A1 ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF CYP4X1, CBR3, TYR MAPT 4740/4885KDM4E 77/4885POLB 3633/4885
US-20150133506-A1 1-ARYL-5-ALKYL PYRAZOLE DERIVATIVE COMPOUNDS, PROCESSES OF MAKING AND METHODS OF USING THEREOF CBR3, CBR1, NR5A2 MAPT 4885/4885KDM4E 3120/4885POLB 4213/4885
US-11629138-B2 Microbiocidal picolinamide derivatives PRF1, CASP1, FPR1 MAPT 3764/4885KDM4E 2969/4885POLB 3534/4885
US-20140080862-A1 ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF CYP4X1, CBR3, TYR MAPT 4740/4885KDM4E 77/4885POLB 3633/4885
US-11629129-B2 Microbiocidal picolinamide derivatives PRF1, CASP1, MSR1 MAPT 3592/4885KDM4E 3192/4885POLB 3215/4885
US-20210186022-A1 MICROBIOCIDAL THIAZOLE DERIVATIVES MSR1, TLR1, IFNG MAPT 4168/4885KDM4E 3260/4885POLB 3655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.